clinical trial · NCT00302211
The "VISION" Trial: Ventavis Inhalation With Sildenafil to Improve and Optimize Pulmonary Arterial Hypertension
Actelion·phase3·terminated·n = 67
Pulmonary HypertensionInhaled Iloprost (5 μg)Inhaled PlaceboSildenafilBosentan
brief summary
The purpose of this multi-center international trial is to evaluate the safety and effectiveness of adding iloprost or placebo (an inactive substance that contains no active study drug) to sildenafil therapy for pulmonary arterial hypertension (PAH). The study will also examine whether patients on sildenafil can reduce the number of iloprost inhalations from the approved 6 doses per day to 4 doses per day.
started
Feb 1, 2006
primary completion
Dec 1, 2007
completion
Jul 1, 2008
last updated
Feb 4, 2025
official title
A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of the Addition of Inhaled Iloprost in Patients With Pulmonary Arterial Hypertension Receiving Oral Sildenafil
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol